Kundandeep Nagi, MD
Ophthalmology · San Antonio, TXNPI 1245494558
Payments from drug & device makers
Across 456 payments — averaging $968.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$361K
- Bausch & Lomb Americas Inc.$46K
- Aerie Pharmaceuticals, Inc.$28K
- Biotissue Holdings Inc.$2K
- Alcon$2K
- Rxsight Inc$414
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$25,86270%
- Travel & lodging$1,5844%
- Food & beverage$9,54326%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 223 | $360,973 |
| Bausch & Lomb Americas Inc. | 29 | $46,047 |
| Aerie Pharmaceuticals, Inc. | 50 | $28,272 |
| Biotissue Holdings Inc. | 22 | $2,108 |
| Alcon | 38 | $1,578 |
| Rxsight Inc | 6 | $414 |
| Amgen(2 entities) | 18 | $340 |
| Novartis | 11 | $219 |
| Akorn, Inc. | 10 | $195 |
| Tarsus Pharmaceuticals, Inc. | 6 | $189 |
| Sight Sciences, Inc. | 2 | $157 |
| Ocular Therapeutix, Inc. | 3 | $153 |
| Akorn Operating Company LLC | 9 | $145 |
| Genentech USA, Inc. | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| NEW World Medical,inc. | 6 | $108 |
| Nova Eye, Inc. | 1 | $105 |
| Sun Pharmaceutical Industries Inc. | 4 | $89 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $88 |
| Thea Pharma Inc. | 5 | $81 |
| Astellas Pharma US Inc | 1 | $25 |
| Harrow Eye, LLC | 1 | $24 |
| Shire North American Group Inc | 1 | $24 |
| Dompe US, Inc. | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$27,629
- Rhopressa$22,847
- Prokera$808
- AmnioGraft$808
- ARGOS$298
- Centurion$253
- OMNI(R) SURGICAL SYSTEM (US)$137
- DURYSTA$135
- VABYSMO$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- Syfovre$125
- AmnioGuard$121
- DEXTENZA$107
- Hydrus Microstent$103
- RXSIGHT CONTACT LENS$101
- RXSIGHT INJECTOR CARTRIDGE$101
- RXSIGHT INJECTOR HANDPIECE$101
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$101
- LIGHT ADJUSTABLE LENS (LAL)$101
How this compares
$441,639 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 753 | $391,958 |
| RocklatanNetarsudil Mesylat/Latanoprost | 618 | $373,002 |
| CombiganBrimonidine Tartrate/Timolol | 551 | $221,476 |
| RhopressaNetarsudil Mesylate | 366 | $213,110 |
| VyzultaLatanoprostene Bunod | 429 | $187,747 |
| RestasisCyclosporine | 85 | $94,513 |
| Alphagan PBrimonidine Tartrate | 184 | $71,443 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 353 | $46,527 |
| Latanoprost | 3,549 | $34,237 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 2,289 | $26,588 |
| Travoprost | 197 | $24,693 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 87 | $24,393 |
| Prednisolone Acetate | 654 | $21,210 |
| Brimonidine Tartrate | 858 | $21,095 |
| Brinzolamide | 90 | $13,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $360,973 | $779,3901,573 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $28,272 | $586,112984 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $46,047 | $187,747429 claims |
| AlconSimbrinza, Azopt | $1,578 | $36,041106 claims |
| Thea Pharma Inc.Iyuzeh | $81 | $9,71325 claims |
| NovartisTravatan Z | $219 | $9,58817 claims |
| Akorn, Inc.Zioptan | $195 | $4,34011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$4.2M
- Gregory ParkhurstSan Antonio$4.1M
- Calvin MeinSan Antonio$1.3M
- James LehmannSan Antonio$1.1M
- Darren BellSan Antonio$906K
- Gregory BruninSan Antonio$709K
- Richard EvansSan Antonio$656K
- Edward RashidSan Antonio$523K
- Kenneth MaverickSan Antonio$485K
- Charles WykoffBellaire$73.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.